AR103962A1 - PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER OF PANCREAS AND OTHER TYPES OF CANCER - Google Patents
PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER OF PANCREAS AND OTHER TYPES OF CANCERInfo
- Publication number
- AR103962A1 AR103962A1 ARP160100717A ARP160100717A AR103962A1 AR 103962 A1 AR103962 A1 AR 103962A1 AR P160100717 A ARP160100717 A AR P160100717A AR P160100717 A ARP160100717 A AR P160100717A AR 103962 A1 AR103962 A1 AR 103962A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- seq
- peptide
- lymphocytes
- present application
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000037029 cross reaction Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente solicitud se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente solicitud se refiere a la inmunoterapia contra el cáncer. La presente solicitud se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión. Reivindicación 1: Péptido que comprende una secuencia de aminoácidos seleccionada entre el grupo de la SEQ ID Nº 1 a la SEQ ID Nº 67, y secuencias variantes de las mismas que son como mínimo homólogas en un 88% a las SEQ ID Nº 1 a la SEQ ID Nº 67, y en que dichas variantes se unen a una o varias moléculas del complejo mayor de histocompatibilidad (MHC) y/o inducen la reacción cruzada de linfocitos T con dicho péptido variante; y una sal farmacéuticamente aceptable del mismo, en la que dicho péptido no es un polipéptido entero.The present application relates to peptides, proteins, nucleic acids and cells intended for use in immunotherapeutic methods. In particular, the present application relates to cancer immunotherapy. The present application also relates to peptide epitopes for T-lymphocytes associated with tumors, alone or in combination with other peptides associated with tumors that, for example, can serve as pharmaceutical active ingredients in vaccine compositions intended to stimulate antitumor immune responses, or stimulate ex I live T lymphocytes that will then be transferred to patients. Peptides bound to major histocompatibility complex (MHC) molecules, or peptides as such, can also be targets of antibodies, soluble T-lymphocyte receptors, and other binding molecules. Claim 1: Peptide comprising an amino acid sequence selected from the group of SEQ ID No. 1 to SEQ ID No. 67, and variant sequences thereof that are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 67, and in which said variants bind to one or several molecules of the major histocompatibility complex (MHC) and / or induce the cross-reaction of T lymphocytes with said variant peptide; and a pharmaceutically acceptable salt thereof, wherein said peptide is not a whole polypeptide.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134253P | 2015-03-17 | 2015-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103962A1 true AR103962A1 (en) | 2017-06-14 |
Family
ID=59256519
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100717A AR103962A1 (en) | 2015-03-17 | 2016-03-17 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER OF PANCREAS AND OTHER TYPES OF CANCER |
| ARP210100474A AR122383A2 (en) | 2015-03-17 | 2021-02-24 | NEW PEPTIDES AND A NEW COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER TYPES OF CANCER |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100474A AR122383A2 (en) | 2015-03-17 | 2021-02-24 | NEW PEPTIDES AND A NEW COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER TYPES OF CANCER |
Country Status (2)
| Country | Link |
|---|---|
| AR (2) | AR103962A1 (en) |
| EA (4) | EA202190898A3 (en) |
-
2016
- 2016-03-17 AR ARP160100717A patent/AR103962A1/en not_active Application Discontinuation
- 2016-03-17 EA EA202190898A patent/EA202190898A3/en unknown
- 2016-03-17 EA EA201990755A patent/EA201990755A1/en unknown
- 2016-03-17 EA EA202190896A patent/EA202190896A3/en unknown
- 2016-03-17 EA EA202190897A patent/EA202190897A3/en unknown
-
2021
- 2021-02-24 AR ARP210100474A patent/AR122383A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR122383A2 (en) | 2022-09-07 |
| EA201990755A1 (en) | 2019-08-30 |
| EA202190896A2 (en) | 2021-07-30 |
| EA202190897A3 (en) | 2021-10-29 |
| EA202190896A3 (en) | 2021-10-29 |
| EA202190898A3 (en) | 2021-10-29 |
| EA202190897A2 (en) | 2021-07-30 |
| EA202190898A2 (en) | 2021-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121587A2 (en) | NEW PEPTIDES AND A NEW PEPTIDE COMBINATION FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER TYPES OF CANCER | |
| PE20181490A1 (en) | TREATMENTS AGAINST CANCER OF THE UTERUS | |
| PE20240645A1 (en) | IMMUNOGENIC PEPTIDE DERIVED FROM HUMAN LEUKOCYTE ANTIGEN (HLA) MOLECULES AS A BIOMARKER IN THE IMMUNOTHERAPY OF VARIOUS TUMORS | |
| CL2020000985A1 (en) | New peptide from seq id no: 24 for use in immunotherapy against lung cancer, including small cell lung cancer and other cancers (divisional application no. 201701819) | |
| CL2020002387A1 (en) | Peptides (seq id no: 39) and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancer (application divisional no. 202002123) | |
| CL2021002461A1 (en) | Peptide, antibody and tcr binding thereto, host cell, activated t-lymphocyte, pharmaceutical composition comprising them, and their uses in cancer immunotherapy (divisional of application no. 201902093) | |
| CR20180423A (en) | NEW PEPTIDES, COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCER (Divisional 2018-0174) | |
| PE20240778A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | |
| MX2018011223A (en) | T-TRANSFECTED LYMPHOCYTES AND T-LYMPHOCYTE RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCER. | |
| CR20180398A (en) | PEPTIDES, COMBINATIONS OF PEPTIDES AND CELLS FOR USE IN IMMUNOTHERAPY AGAINST BLADDER CANCER AND OTHER TYPES OF CANCER | |
| CR20180051A (en) | NEW CELLULAR EPITHOPES AND NEW COMBINATIONS OF CELLULAR EPITHOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER TYPES OF CANCER. | |
| CR20180245A (en) | NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TYPES OF CANCER | |
| CR20180191A (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST MICROCHATIC LUNG CANCER AND OTHER TYPES OF CANCER | |
| CR20180491A (en) | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST AMICROCYTIC LUNG CANCER AND OTHER TYPES OF CANCER | |
| CO2018000245A2 (en) | Peptides and combinations of peptides for immunotherapy against pancreatic cancer and other types of cancer | |
| MX2022002193A (en) | NEW PEPTIDES AND SUPPORT STRUCTURES FOR USE IN IMMUNOTHERAPY AGAINST SPIDERMOID CARCINOMA OF THE HEAD AND NECK AND OTHER TYPES OF CANCER. | |
| PE20181897A1 (en) | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER TYPES OF CANCER | |
| CL2018000545A1 (en) | New peptides, combinations of peptides and supports for use in the immunotherapeutic treatment of various types of cancer. | |
| CO2018012914A2 (en) | Peptides and combination of peptides as targets and for immunotherapy against gallbladder cancer and cholangiocarcinoma, as well as other types of cancer | |
| CO2017010830A2 (en) | Peptides and combinations of peptides and supports | |
| CL2020001563A1 (en) | Peptides (seq id no. 64, seq id no. 2 to seq id no. 63, seq id no. 65 to seq id no. 118, and seq id no. 120 to seq id no. 149), combinations of peptides and cells for use in immunotherapy against urinary bladder cancer and other cancers. (divisional request 201802360) | |
| CO2018000247A2 (en) | New cell epitopes and new combinations of cell epitopes for use in the immunotherapy of myeloma and other types of cancer | |
| AR114737A1 (en) | IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO A * 01 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS | |
| AR103962A1 (en) | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER OF PANCREAS AND OTHER TYPES OF CANCER | |
| CL2021001525A1 (en) | Novel peptides and novel peptide combinations as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma, as well as other types of cancer (divisional application no. 201803293) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |